InMed recently reported results for the first quarter of FY19 and continues to make solid progress in bringing INM-750 for epidermolysis bullosa (EB) into the clinic by H219. So far, its selected formulation has demonstrated good drug penetration as a topical formulation, a clean safety profile and that each of the two cannabinoid components plays an important and independent role in combating EB, which is an especially important finding from a regulatory point of view for any combination product.  Additionally, the company’s biosynthesis program is tracking on schedule.

We have adjusted our valuation to C$232m or C$1.36 per basic share (C$1.05 per diluted share) from C$234m or C$1.37 per basic share (C$1.05 per diluted share) solely due to lower net cash, otherwise our valuation estimates are the same. The company had C$24.8m in cash at 30 September and we believe this provides runway into FY21. Click here to view the full report.

All reports published by Edison are available to download free of charge from its websitewww.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Maxim Jacobs, +1 646 653 7027Briana Warschun, +1 646 653 7031healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:  LinkedIn        https://www.linkedin.com/company/edison-investment-research Twitter           www.twitter.com/Edison_Inv_Res YouTube       www.youtube.com/edisonitv